{"id":"https://openalex.org/W4389239771","doi":"https://doi.org/10.1158/1535-7163.targ-23-c013","title":"Abstract C013: Clinical biomarkers based on PK/PD modeling to guide the development for a first-in-class, highly selective SMARCA2 (BRM) degrader, PRT3789","display_name":"Abstract C013: Clinical biomarkers based on PK/PD modeling to guide the development for a first-in-class, highly selective SMARCA2 (BRM) degrader, PRT3789","publication_year":2023,"publication_date":"2023-12-01","ids":{"openalex":"https://openalex.org/W4389239771","doi":"https://doi.org/10.1158/1535-7163.targ-23-c013"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-23-c013","doi":"https://doi.org/10.1158/1535-7163.targ-23-c013","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-23-c013","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1158/1535-7163.targ-23-c013","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Min Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Min Wang","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101927522","display_name":"Andrew Moore","orcid":"https://orcid.org/0009-0005-4080-5676","observed_orcids":["https://orcid.org/0009-0005-4080-5676"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Moore","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069730078","display_name":"Alexander Grego","orcid":"https://orcid.org/0009-0000-8724-7003","observed_orcids":["https://orcid.org/0009-0000-8724-7003"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander Grego","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034085965","display_name":"Miles Cowart","orcid":"https://orcid.org/0009-0006-1839-9242","observed_orcids":["https://orcid.org/0009-0006-1839-9242"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Miles Cowart","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004443645","display_name":"Joseph D. Rager","orcid":"https://orcid.org/0009-0004-6008-9630","observed_orcids":["https://orcid.org/0009-0004-6008-9630"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Rager","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033611298","display_name":"Gina Paris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gina Paris","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023093205","display_name":"Koichi Ito","orcid":"https://orcid.org/0000-0003-1421-3122","observed_orcids":["https://orcid.org/0000-0003-1421-3122"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Koichi Ito","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110623859","display_name":"Naveen Babbar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naveen Babbar","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004633647","display_name":"Sandy Geeganage","orcid":"https://orcid.org/0009-0002-4608-8012","observed_orcids":["https://orcid.org/0009-0002-4608-8012"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sandy Geeganage","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078861517","display_name":"Peegy Scherle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peegy Scherle","raw_affiliation_strings":["1Prelude Therapeutics, Inc., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Prelude Therapeutics, Inc., Wilmington, DE,","institution_ids":["https://openalex.org/I4405265449"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060435781","display_name":"Neha Bhagwat","orcid":"https://orcid.org/0009-0002-5766-0272","observed_orcids":["https://orcid.org/0009-0002-5766-0272"]},"institutions":[{"id":"https://openalex.org/I4405265449","display_name":"Prelude Therapeutics Incorporated (United States)","ror":"https://ror.org/04v7ftc96","country_code":"US","type":"company","lineage":["https://openalex.org/I4405265449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neha Bhagwat","raw_affiliation_strings":["2Prelude Therapeutics, Inc., WILMINGTON, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Prelude Therapeutics, Inc., WILMINGTON, DE","institution_ids":["https://openalex.org/I4405265449"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405265449"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"12_Supplement","first_page":"C013","last_page":"C013"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9721999764442444,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.9721999764442444,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.026599999517202377,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brg1","display_name":"SMARCA4","score":0.6949999928474426},{"id":"https://openalex.org/keywords/swi-snf-chromatin-remodeling","display_name":"SWI/SNF chromatin remodeling","score":0.8479999899864197},{"id":"https://openalex.org/keywords/target-engagement-biomarkers","display_name":"target engagement biomarkers","score":0.6859999895095825},{"id":"https://openalex.org/keywords/pharmacokinetic-pharmacodynamic-modeling","display_name":"pharmacokinetic-pharmacodynamic modeling","score":0.8659999966621399},{"id":"https://openalex.org/keywords/degradation-kinetics","display_name":"degradation kinetics","score":0.6819999814033508},{"id":"https://openalex.org/keywords/immunoassay-development","display_name":"immunoassay development","score":0.6710000038146973},{"id":"https://openalex.org/keywords/differential-gene-expression","display_name":"differential gene expression","score":0.6470000147819519},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8420000076293945},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.5680000185966492},{"id":"https://openalex.org/keywords/tumor-immunohistochemistry","display_name":"tumor immunohistochemistry","score":0.4860000014305115}],"concepts":[{"id":"https://openalex.org/C80828422","wikidata":"https://www.wikidata.org/wiki/Q18031595","display_name":"SMARCA4","level":5,"score":0.8727359771728516},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.6126048564910889},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5329810976982117},{"id":"https://openalex.org/C167227067","wikidata":"https://www.wikidata.org/wiki/Q5113739","display_name":"Chromatin remodeling","level":4,"score":0.4999504089355469},{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.4701564311981201},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4324203133583069},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3790842890739441},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3686196506023407},{"id":"https://openalex.org/C83640560","wikidata":"https://www.wikidata.org/wiki/Q180951","display_name":"Chromatin","level":3,"score":0.2963789105415344},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.27466684579849243},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.22614112496376038},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.11396154761314392}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-23-c013","doi":"https://doi.org/10.1158/1535-7163.targ-23-c013","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-23-c013","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.targ-23-c013","doi":"https://doi.org/10.1158/1535-7163.targ-23-c013","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-23-c013","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362543374","https://openalex.org/W4389240577","https://openalex.org/W4282925667","https://openalex.org/W4402560061","https://openalex.org/W4414465618","https://openalex.org/W4393085484","https://openalex.org/W4409625770","https://openalex.org/W4387811462","https://openalex.org/W4409689517","https://openalex.org/W4393071848"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"The":[2,260,321],"SWI/SNF":[3],"family":[4],"of":[5,19,26,28,30,45,69,105,115,133,165,183,209,240,268,276,278,309,347,362,388,464],"chromatin-remodeling":[6],"complexes":[7],"is":[8,79,88],"frequently":[9],"dysregulated":[10],"in":[11,16,24,38,43,74,92,97,144,168,187,215,232,252,258,319,358,366,378,398,412],"multiple":[12,39],"tumor":[13,40,216,329,349,367],"types,":[14,41],"resulting":[15,23],"aberrant":[17],"expression":[18,214,303,308,365,397],"genes.":[20],"Damaging":[21],"mutations":[22,354,377],"loss":[25,104],"function":[27],"one":[29],"its":[31],"core":[32],"catalytic":[33,59],"subunits":[34],"SMARCA4":[35,106,212,353,363,380],"(BRG1)":[36],"occur":[37],"including":[42],"5-10%":[44],"non-small":[46],"cell":[47],"lung":[48],"cancer":[49,76],"(NSCLC).":[50],"SMARCA4-deleted":[51],"cells":[52,368],"become":[53],"highly":[54,455],"dependent":[55],"on":[56,118,126,220,294,307,394,445,470],"the":[57,111,157,163,207,221,236,248,295,379,385,450,465],"other":[58],"subunit,":[60],"SMARCA2":[61,70,85,166,184,197,210,271,316,342,457],"(BRM),":[62],"for":[63,162,181,206,270,340,452],"their":[64],"survival,":[65],"therefore":[66],"selective":[67,84,456],"degradation":[68,112,198,237,318,391],"has":[71],"therapeutic":[72],"potential":[73],"these":[75],"types.":[77],"PRT3789":[78,116,241,249,411,460],"a":[80,93,131,264,273,300,332,413,453],"first-in-class,":[81,454],"potent":[82],"and":[83,152,211,242,254,288,326,336,343,375,392,473],"degrader":[86],"that":[87,136,190,313],"currently":[89],"under":[90],"evaluation":[91],"Phase":[94,146,414],"1":[95,147,415],"study":[96],"patients":[98],"with":[99,103,173,194,272,315,331,351,373,410],"advanced":[100],"solid":[101],"tumors":[102],"(NCT05639751).":[107],"We":[108,383],"deeply":[109],"characterized":[110,235],"kinetic":[113,238],"parameters":[114,239],"based":[117,306,444],"preclinical":[119],"PK/PD":[120,253,446],"studies,":[121],"which":[122,400],"enabled":[123],"dose-selection.":[124],"Based":[125,293],"this":[127,145,359],"modeling,":[128],"we":[129,298],"developed":[130,161,180,219,299],"suite":[132],"biomarker":[134],"assays":[135],"can":[137],"be":[138,192,402],"used":[139,245,403],"to":[140,196,246,291,404,448],"assess":[141,405],"target":[142,406],"engagement":[143,407],"study.":[148,417],"Methods:":[149],"A":[150,175,345],"sensitive":[151,386],"quantitative":[153],"plate-based":[154],"immunoassay":[155],"utilizing":[156],"MSD\u00ae":[158,261],"platform":[159,225],"was":[160,179,218,243,371],"measurement":[164],"protein":[167,213,317,364,390],"human":[169],"PBMCs":[170],"following":[171,408],"treatment":[172,409],"PRT3789.":[174,200],"secondary,":[176],"qPCR-based":[177],"assay":[178,205,262,323],"assessment":[182,208,387],"transcriptional":[185],"targets":[186],"peripheral":[188],"blood":[189],"may":[191],"associated":[193,372],"response":[195],"by":[199,369],"Additionally,":[201],"an":[202,310],"immunohistochemistry":[203],"(IHC)":[204],"tissue":[217],"Leica":[222],"BOND":[223],"III":[224],"using":[226],"commercially":[227],"available":[228],"antibodies.":[229],"Results:":[230],"Detailed":[231],"vitro":[233],"enzymology":[234],"successfully":[244],"predict":[247],"effects":[250,393],"observed":[251],"xenograft":[255],"efficacy":[256],"studies":[257],"mice.":[259],"demonstrated":[263,324],"wide":[265],"dynamic":[266,333],"range":[267,335],"detection":[269],"lower":[274],"level":[275],"quantification":[277],"23":[279],"pg/mL,":[280],"as":[281,283],"well":[282],"exhibiting":[284],"acceptable":[285],"spike":[286],"recovery":[287],"minimal":[289],"cross-reactivity":[290],"SMARCA4.":[292,344],"qPCR":[296],"assay,":[297],"differential":[301],"gene":[302,396],"(DGE)":[304],"score":[305],"8-gene":[311],"panel":[312,346],"correlates":[314],"PBMCs.":[320],"IHC":[322,370],"discrete":[325],"robust":[327],"nuclear":[328],"staining":[330],"intensity":[334],"limited":[337],"cytoplasmic":[338],"background":[339],"both":[341],"NSCLC":[348],"samples":[350],"known":[352],"were":[355],"further":[356],"evaluated":[357],"assay.":[360],"Loss":[361],"nonsense":[374],"frameshift":[376],"gene.":[381],"Conclusions:":[382],"demonstrate":[384],"SMARAC2":[389],"downstream":[395],"PBMCs,":[399],"will":[401],"clinical":[416],"Citation":[418],"Format:":[419],"Min":[420],"Wang,":[421],"Andrew":[422],"Moore,":[423],"Alexander":[424],"Grego,":[425],"Miles":[426],"Cowart,":[427],"Joseph":[428],"Rager,":[429],"Gina":[430],"Paris,":[431],"Koichi":[432],"Ito,":[433],"Naveen":[434],"Babbar,":[435],"Sandy":[436],"Geeganage,":[437],"Peegy":[438],"Scherle,":[439],"Neha":[440],"Bhagwat.":[441],"Clinical":[442],"biomarkers":[443],"modeling":[447],"guide":[449],"development":[451],"(BRM)":[458],"degrader,":[459],"[abstract].":[461],"In:":[462],"Proceedings":[463],"AACR-NCI-EORTC":[466],"Virtual":[467],"International":[468],"Conference":[469],"Molecular":[471],"Targets":[472],"Cancer":[474,485],"Therapeutics;":[475],"2023":[476],"Oct":[477],"11-15;":[478],"Boston,":[479],"MA.":[480],"Philadelphia":[481],"(PA):":[482],"AACR;":[483],"Mol":[484],"Ther":[486],"2023;22(12":[487],"Suppl):Abstract":[488],"nr":[489],"C013.":[490]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2023-12-02T00:00:00"}